LT3682B - Method for preparing amino acid derivatives and pharmaceuthical compositions thereof - Google Patents

Method for preparing amino acid derivatives and pharmaceuthical compositions thereof Download PDF

Info

Publication number
LT3682B
LT3682B LTIP862A LTIP862A LT3682B LT 3682 B LT3682 B LT 3682B LT IP862 A LTIP862 A LT IP862A LT IP862 A LTIP862 A LT IP862A LT 3682 B LT3682 B LT 3682B
Authority
LT
Lithuania
Prior art keywords
formula
compound
acid
hydroxy
isoquinoline
Prior art date
Application number
LTIP862A
Other languages
English (en)
Lithuanian (lt)
Inventor
Joseph Armstrong Martin
Sally Redshaw
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of LTIP862A publication Critical patent/LTIP862A/xx
Publication of LT3682B publication Critical patent/LT3682B/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/021—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)n-C(=0)-, n being 5 or 6; for n > 6, classification in C07K5/06 - C07K5/10, according to the moiety having normal peptide bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Confectionery (AREA)
  • Cleaning Or Clearing Of The Surface Of Open Water (AREA)
  • Measurement Of Force In General (AREA)
LTIP862A 1989-12-11 1993-08-16 Method for preparing amino acid derivatives and pharmaceuthical compositions thereof LT3682B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB898927913A GB8927913D0 (en) 1989-12-11 1989-12-11 Amino acid derivatives
SG120493A SG120493G (en) 1989-12-11 1993-11-02 N-tert-Butyl-decahydro-2(3-amino-2-hydroxy-4-phenyl-butyl) isoquinoline-3-carboxamide and asparaginyl derivatives thereof

Publications (2)

Publication Number Publication Date
LTIP862A LTIP862A (en) 1995-03-27
LT3682B true LT3682B (en) 1996-01-25

Family

ID=26296345

Family Applications (1)

Application Number Title Priority Date Filing Date
LTIP862A LT3682B (en) 1989-12-11 1993-08-16 Method for preparing amino acid derivatives and pharmaceuthical compositions thereof

Country Status (48)

Country Link
US (1) US5196438A (OSRAM)
EP (1) EP0432695B1 (OSRAM)
JP (1) JP2807093B2 (OSRAM)
KR (1) KR970005912B1 (OSRAM)
CN (2) CN1066329C (OSRAM)
AT (1) ATE122661T1 (OSRAM)
AU (1) AU634319B2 (OSRAM)
BG (1) BG51452A3 (OSRAM)
BR (1) BR9006264A (OSRAM)
CA (1) CA2030433C (OSRAM)
CU (1) CU22305A3 (OSRAM)
CZ (1) CZ280558B6 (OSRAM)
DE (2) DE19675051I2 (OSRAM)
DK (1) DK0432695T3 (OSRAM)
DZ (1) DZ1467A1 (OSRAM)
EG (1) EG19722A (OSRAM)
ES (1) ES2072959T3 (OSRAM)
FI (2) FI100883B (OSRAM)
GB (2) GB8927913D0 (OSRAM)
GR (1) GR3017114T3 (OSRAM)
HK (1) HK129093A (OSRAM)
HR (1) HRP930341B1 (OSRAM)
HU (2) HU207298B (OSRAM)
ID (1) ID1018B (OSRAM)
IE (1) IE67523B1 (OSRAM)
IL (1) IL96550A (OSRAM)
IN (1) IN172553B (OSRAM)
IS (1) IS1803B (OSRAM)
LT (1) LT3682B (OSRAM)
LU (1) LU90014I2 (OSRAM)
LV (1) LV5738B4 (OSRAM)
MA (1) MA22014A1 (OSRAM)
MC (1) MC2195A1 (OSRAM)
MT (1) MTP1075B (OSRAM)
MW (1) MW8890A1 (OSRAM)
MX (1) MX173630B (OSRAM)
NL (1) NL970013I2 (OSRAM)
NO (1) NO176566C (OSRAM)
OA (1) OA09334A (OSRAM)
PL (1) PL165225B1 (OSRAM)
PT (1) PT96145B (OSRAM)
RO (1) RO107942B1 (OSRAM)
RU (1) RU2071470C1 (OSRAM)
SG (1) SG120493G (OSRAM)
SI (1) SI9012315B (OSRAM)
SK (1) SK576590A3 (OSRAM)
ZA (1) ZA909743B (OSRAM)
ZW (1) ZW17490A1 (OSRAM)

Families Citing this family (121)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040122000A1 (en) * 1981-01-07 2004-06-24 Vertex Pharmaceuticals Incorporated. Inhibitors of aspartyl protease
US6878728B1 (en) 1999-06-11 2005-04-12 Vertex Pharmaceutical Incorporated Inhibitors of aspartyl protease
US5614533A (en) * 1987-03-13 1997-03-25 Bio-Mega/Boehringer Ingelheim Research, Inc. Substituted pipecolinic acid derivatives as HIV protease inhibitors
USH1649H (en) 1987-07-31 1997-05-06 Barrish; Joel C. HIV protease inhibitor combinations
CA1340588C (en) * 1988-06-13 1999-06-08 Balraj Krishan Handa Amino acid derivatives
GB8927915D0 (en) * 1989-12-11 1990-02-14 Hoffmann La Roche Novel alcohols
US5430041A (en) * 1991-05-10 1995-07-04 Hoffmann-La Roche Inc. Amino acid derivatives having antiviral activity
CN1071930A (zh) * 1991-07-10 1993-05-12 伊莱利利公司 用作治疗艾滋病的人免疫缺陷病毒蛋白酶的抑制剂
US5508407A (en) * 1991-07-10 1996-04-16 Eli Lilly And Company Retroviral protease inhibitors
WO1993008184A1 (en) * 1991-10-23 1993-04-29 Merck & Co., Inc. Hiv protease inhibitors
US5413999A (en) * 1991-11-08 1995-05-09 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
CA2195027C (en) * 1991-11-08 2000-01-11 Joseph P. Vacca Hiv protease inhibitors useful for the treatment of aids
BR9306058A (pt) 1992-03-11 1997-11-18 Narhex Ltd Derivados de amina de hidrocarbonetos oxo- e hidroxi- substituidos
US5888992A (en) 1992-03-11 1999-03-30 Narhex Limited Polar substituted hydrocarbons
US6071895A (en) 1992-03-11 2000-06-06 Narhex Limited Polar-substituted hydrocarbons
DK0560268T3 (da) * 1992-03-13 1995-06-12 Bio Mega Boehringer Ingelheim Substituerede pipecolinsyrederivater som HIV-proteasehæmmere
EP1447398A1 (en) * 1992-05-21 2004-08-18 Monsanto Company Retroviral protease inhibitors
US5559256A (en) * 1992-07-20 1996-09-24 E. R. Squibb & Sons, Inc. Aminediol protease inhibitors
DK0810209T3 (da) 1992-08-25 2002-08-12 Monsanto Co Alpha - and beta-aminosyre-hydroxyethylaminosulfonamider til anvendelse som inhibitorer af retrovirale proteaser
IS2334B (is) 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
US5723490A (en) * 1992-09-08 1998-03-03 Vertex Pharmaceuticals Incorporated THF-containing sulfonamide inhibitors of aspartyl protease
US5783701A (en) * 1992-09-08 1998-07-21 Vertex Pharmaceuticals, Incorporated Sulfonamide inhibitors of aspartyl protease
TW372972B (en) * 1992-10-23 1999-11-01 Novartis Ag Antiretroviral acyl compounds
US5380849A (en) * 1992-11-09 1995-01-10 Merck & Co., Inc. Process for optically pure decahydroisoqiunolines
US5430150A (en) * 1992-12-16 1995-07-04 American Cyanamid Company Retroviral protease inhibitors
US5434265A (en) * 1992-12-22 1995-07-18 Eli Lilly And Company Inhibitors of HIV protease
US5733906A (en) * 1993-10-12 1998-03-31 Eli Lilly And Company Inhibitors of HIV Protease useful for the treatment of Aids
US5846993A (en) * 1992-12-22 1998-12-08 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
MX9308016A (es) * 1992-12-22 1994-08-31 Lilly Co Eli Compuestos inhibidores de la proteasa del virus de la inmunodeficiencia humana, procedimiento para su preparacion y formulacion farmaceutica que los contiene.
MX9308025A (es) * 1992-12-22 1994-08-31 Lilly Co Eli Compuestos inhibidores de la proteasa del virus dela inmunodeficiencia humana, procedimiento para supreparacion y formulacion farmaceutica que los contiene.
US5484926A (en) * 1993-10-07 1996-01-16 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
US5491166A (en) * 1992-12-22 1996-02-13 Eli Lilly And Company Inhibitors of HIV protease useful for the treatment of AIDS
AU6161794A (en) * 1993-01-17 1994-08-15 Schering Corporation Peptides having anti-hiv activity
US5939430A (en) * 1993-02-22 1999-08-17 Merrell Pharmaceuticals Inc. Combinations of retroviral inhibitors
US5455353A (en) * 1993-03-24 1995-10-03 Hoffmann-La Roche Inc. 4-(benzyl-2-oxo-oxazolidin-5 ylmethyl)N tertbutyl-decahydroisoquinoline-3-carboxamides
ATE172970T1 (de) * 1993-07-15 1998-11-15 Hoffmann La Roche Verfahren zur herstellung eines n-tert.butylamids
CA2182090A1 (en) * 1994-02-02 1995-08-10 William Joseph Hornback Hiv protease inhibitors and intermediates
US6127372A (en) * 1994-03-07 2000-10-03 Vertex Pharmaceuticals, Incorporated Sulfonamide inhibitors of aspartyl protease
US5527829A (en) * 1994-05-23 1996-06-18 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
US5470979A (en) * 1994-07-01 1995-11-28 American Cyanamid Company Asymmetric synthesis of bicyclic amino acid esters
US5523463A (en) * 1994-09-23 1996-06-04 Hoffmann-La Roche Inc. Method of producing halogenated and alpha-aminoalchohols
US5591885A (en) * 1994-09-23 1997-01-07 Hoffman-La Roche Inc. Process for the preparation of halogenated α-aminoketone compounds
US5691372A (en) * 1995-04-19 1997-11-25 Vertex Pharmaceuticals Incorporated Oxygenated-Heterocycle containing sulfonamide inhibitors of aspartyl protease
TR199701541T1 (xx) * 1995-06-06 1998-03-21 F.Hoffmann-La Roche Ag Proteinaz engelleyici ve tekli gliserid i�eren farmas�tik bile�im.
US6008228A (en) * 1995-06-06 1999-12-28 Hoffman-La Roche Inc. Pharmaceutical compositions containing proteinase inhibitors
US6004957A (en) * 1995-06-07 1999-12-21 Vertex Pharmaceuticals, Incorporated Sulfonamide inhibitors of aspartyl protease
US6037157A (en) 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
AU759386B2 (en) * 1995-06-29 2003-04-10 Abbvie Inc. Use of Ritonavir (ABT-538) for improving the pharmacokinetics of drugs metabolized by cytochrome P450 in a method of treating AIDS
JP2000500156A (ja) 1995-11-13 2000-01-11 フールマン，ヘラルド ヒルから得られる抗ウイルス性単離物
US5914332A (en) * 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
US5883252A (en) * 1996-01-26 1999-03-16 Vertex Pharmaceuticals Incorporated Aspartyl protease inhibitors
US5587481A (en) * 1996-02-20 1996-12-24 The Monsanto Company Preparation of (S)-decahydroisoquinoline-3-carboxylic acid t-butylamide
EP0823424A1 (de) * 1996-08-09 1998-02-11 F. Hoffmann-La Roche Ag Verfahren zur Herstellung von Chinargin
US5914404A (en) * 1996-08-09 1999-06-22 Hoffmann-La Roche Inc. Process for the preparation of quinargine
US5705647A (en) * 1996-09-05 1998-01-06 Agouron Pharmaceuticals, Inc. Intermediates for making HIV-protease inhibitors
US5925759A (en) 1996-09-05 1999-07-20 Agouron Pharmaceuticals, Inc. Methods of making HIV-protease inhibitors and intermediates for making HIV-protease inhibitors
US5962725A (en) 1996-09-05 1999-10-05 Agouron Pharmaceuticals, Inc. Intermediate compounds useful for making HIV protease inhibitors such as nelfinavir
US6232333B1 (en) 1996-11-21 2001-05-15 Abbott Laboratories Pharmaceutical composition
DE59709770D1 (de) 1996-12-11 2003-05-15 Hoffmann La Roche Verfahren zur Herstellung gemischter Anhydride
US6001851A (en) * 1997-03-13 1999-12-14 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
US6084107A (en) * 1997-09-05 2000-07-04 Agouron Pharmaceuticals, Inc. Intermediates for making HIV-protease inhibitors
US6143742A (en) * 1997-12-11 2000-11-07 Fuisz Technologies Ltd Treatment for necrotizing infections
US6436989B1 (en) 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
FR2779653B1 (fr) 1998-06-11 2002-12-20 Inst Nat Sante Rech Med Utilisation de composes modulateurs du proteasome en therapie
CA2335477C (en) * 1998-06-19 2010-11-30 Vertex Pharmaceuticals Incorporated Sulfonamide inhibitors of aspartyl protease
AU756479B2 (en) * 1998-10-21 2003-01-16 Astellas Pharma Inc. Vitreous form of known bradykinin antagonist
KR100277723B1 (ko) 1998-12-14 2001-01-15 남창우 광학적으로 순수한 데카하이드로이소퀴놀린카르복사미드의 연속제조공정
US7115584B2 (en) * 1999-01-22 2006-10-03 Emory University HIV-1 mutations selected for by β-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine
US7635690B2 (en) * 1999-01-22 2009-12-22 Emory University HIV-1 mutations selected for by β-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine
US6765019B1 (en) * 1999-05-06 2004-07-20 University Of Kentucky Research Foundation Permeable, water soluble, non-irritating prodrugs of chemotherapeutic agents with oxaalkanoic acids
ES2265946T3 (es) * 1999-06-04 2007-03-01 Abbott Laboratories Formulaciones farmaceuticas mejoradas que contienen ritonavir.
JP2003504383A (ja) * 1999-07-20 2003-02-04 メルク エンド カムパニー インコーポレーテッド アルファ−ヒドロキシ−ガンマ−［［（炭素環式−又はヘテロ環式−置換）アミノ］カルボニル］アルカンアミド誘導体及びこれらの使用
US6589962B1 (en) 1999-07-20 2003-07-08 Merck & Co., Inc. Alpha-hydroxy-gamma-[[(carbocyclic-or heterocyclic-substituted)amino]carbonyl]alkanamide derivatives and uses thereof
EP1242426B1 (en) 1999-11-24 2007-10-31 Merck & Co., Inc. Gamma-hydroxy-2-(fluoroalkylaminocarbonyl)-1-piperazinepentanamides as hiv protease inhibitors
IT1313682B1 (it) * 1999-11-25 2002-09-09 Archimica Spa Procedimento per la preparazione di (s)-n-terbutil-1,2,3,4-tetraidroisochinolin-3-carbossiammide.
BR0011864A (pt) 2000-01-19 2004-07-20 Abbott Lab Formulações farmacêuticas
US6448245B1 (en) 2000-05-04 2002-09-10 The United States Of America As Represented By The Department Of Health And Human Services Methods of and compounds for inhibiting calpains
IT1318986B1 (it) * 2000-10-09 2003-09-19 Archimica S P A Ora Clariant L Procedimento per la preparazione di (s)-n-terbutil-1,2,3,4-tetraidroisochinolin-3-carbossiammide.
GB0028483D0 (en) 2000-11-22 2001-01-10 Hoffmann La Roche Hydroxyethylamine HIV protease inhibitors
US20030191121A1 (en) * 2001-08-09 2003-10-09 Miller Ross A. Piperazine carboxamide intermediates of HIV protease inhibitors and processes for their preparation
EP1463807A4 (en) 2001-12-19 2006-04-12 Bristol Myers Squibb Co FORMATHYDROGENASE FROM PICHIA PASTORIS AND USES THEREOF
CA2477088A1 (en) 2002-02-22 2003-10-02 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
US20040067216A1 (en) * 2002-02-22 2004-04-08 Karki Shyam B. Hiv protease inhibitors supported on cation exchange resins for oral administration
US7157489B2 (en) * 2002-03-12 2007-01-02 The Board Of Trustees Of The University Of Illinois HIV protease inhibitors
US7115652B2 (en) * 2002-06-17 2006-10-03 Sunesis Pharmaceuticals, Inc. Aspartyl protease inhibitors
EP1515944A1 (en) * 2002-06-17 2005-03-23 Sunesis Pharmaceuticals, Inc. Aspartyl protease inhibitors
RS20060009A (sr) * 2003-07-11 2008-06-05 F.Hoffmann-La Roche Ag., Oralni oblik za doziranje sakvinavir mezilata
EP1604662A1 (en) * 2004-06-08 2005-12-14 Santhera Pharmaceuticals (Deutschland) Aktiengesellschaft 1-[(3R)-Amino-4-(2-fluoro-phenyl)-butyl]-pyrrolidine-(2R)-carboxylic acid benzyl amine derivatives and related compounds as dipeptidyl peptidase IV (DPP-IV) inhibitors for the treatment of type 2 diabetes mellitus
PL216369B1 (pl) 2004-07-27 2014-03-31 Gilead Sciences Pochodne fosfonianowe, kompozycje farmaceutyczne zawierające te pochodne oraz zastosowanie tych pochodnych do wytwarzania leku do hamowania wirusa HIV
WO2006134612A1 (en) * 2005-06-16 2006-12-21 Hetero Drugs Limited A process for the preparation of saquinavir using novel intermediate
KR101518079B1 (ko) 2007-03-12 2015-05-06 넥타르 테라퓨틱스 올리고머-프로테아제 억제제 컨주게이트
CA2691736A1 (en) * 2007-06-29 2009-01-08 Gilead Sciences, Inc. Combination of 6-(3-chloro-2-fluorobenzyl)-1-[(2s)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid and lopinavir for the treatment of a viral infection in a human
EP2167088A1 (en) * 2007-06-29 2010-03-31 Gilead Sciences, Inc. Therapeutic compositions and the use thereof
US20100093811A1 (en) * 2007-09-25 2010-04-15 Coburn Craig A Hiv protease inhibitors
WO2009114151A1 (en) * 2008-03-12 2009-09-17 Nektar Therapeutics Oligomer-amino acid and olgomer-atazanavir conjugates
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
MX2011006152A (es) 2008-12-09 2011-07-28 Gilead Sciences Inc Moduladores de receptores tipo toll.
CN102753563A (zh) * 2008-12-23 2012-10-24 吉利德制药有限责任公司 核苷类似物
SG172363A1 (en) 2008-12-23 2011-07-28 Pharmasset Inc Synthesis of purine nucleosides
AR074897A1 (es) 2008-12-23 2011-02-23 Pharmasset Inc Fosforamidatos de nucleosidos
CA2762582A1 (en) 2009-05-27 2010-12-02 Merck Sharp & Dohme Corp. Hiv protease inhibitors
EP2440249A2 (en) 2009-06-12 2012-04-18 Nektar Therapeutics Covalent conjugates comprising a protease inhibitor, a water-soluble, non-peptidic oligomer and a lipophilic moiety
DE102010004957A1 (de) 2010-01-14 2011-07-21 Universitätsklinikum Jena, 07743 Biologisch wirksame Moleküle zur Beeinflussung von Virus-, Bakterien-, Parasiten-infizierten Zellen und/oder Tumorzellen und Verfahren zu deren Anwendung
US20110223131A1 (en) 2010-02-24 2011-09-15 Gilead Sciences, Inc. Antiviral compounds
WO2011123668A2 (en) 2010-03-31 2011-10-06 Pharmasset, Inc. Stereoselective synthesis of phosphorus containing actives
WO2012055031A1 (en) 2010-10-28 2012-05-03 Merck Canada Inc. Hiv protease inhibitors
EP2392926A1 (en) 2011-02-09 2011-12-07 Roche Diagnostics GmbH Urinary biomarkers in HIV infected subjects
US9133157B2 (en) 2011-10-26 2015-09-15 Merck Canada Inc. HIV protease inhibitors
WO2013105118A1 (en) 2012-01-10 2013-07-18 Council Of Scientific & Industrial Research A process for synthesis of syn azido epoxide and its use as intermediate the synthesis of amprenavir & saquinavir
AR092489A1 (es) 2012-09-11 2015-04-22 Merck Sharp & Dohme Inhibidores de proteasa del vih
CA2889903C (en) 2012-10-29 2021-03-09 Manjinder Singh Phull Antiviral phosphonate analogues and process for preparation thereof
WO2015013835A1 (en) 2013-07-31 2015-02-05 Merck Sharp & Dohme Corp. Piperazine derivatives as hiv protease inhibitors
EP3083609B1 (en) 2013-12-19 2018-08-15 Merck Sharp & Dohme Corp. Hiv protease inhibitors
WO2015095276A1 (en) 2013-12-19 2015-06-25 Merck Sharp & Dohme Corp. Hiv protease inhibitors
WO2015134366A1 (en) 2014-03-06 2015-09-11 Merck Sharp & Dohme Corp. Hiv protease inhibitors
WO2015138220A1 (en) 2014-03-10 2015-09-17 Merck Sharp & Dohme Corp. Piperazine derivatives as hiv protease inhibitors
WO2016001907A1 (en) 2014-07-02 2016-01-07 Prendergast Patrick T Mogroside iv and mogroside v as agonist/stimulator/un-blocking agent for toll-like receptor 4 and adjuvant for use in human/animal vaccine and to stimulate immunity against disease agents.
JP6522732B2 (ja) 2014-07-11 2019-05-29 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖを治療するためのトール様受容体の調節因子
WO2016069955A1 (en) 2014-10-29 2016-05-06 Wisconsin Alumni Research Foundation Boronic acid inhibitors of hiv protease
EP3349757A1 (en) 2015-09-15 2018-07-25 Gilead Sciences, Inc. Modulators of toll-like recptors for the treatment of hiv
WO2021209563A1 (en) 2020-04-16 2021-10-21 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0346847A2 (en) 1988-06-13 1989-12-20 F. Hoffmann-La Roche Ag Amino acid derivatives

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB933968A (en) * 1960-10-26 1963-08-14 May & Baker Ltd New phthalimide derivatives
US4123543A (en) * 1971-09-16 1978-10-31 Ab Kabi Derivatives of substituted indoline lactans with effect on the central nervous system
US3901897A (en) * 1972-10-05 1975-08-26 Squibb & Sons Inc 1,2,3,4,4a,5,6,7-octahydro-7-aryl-isoquinolines and derivatives thereof
US4329473A (en) * 1979-06-01 1982-05-11 Almquist Ronald G Oxoalkanoic acid derivatives as inhibitors of angiotensin converting enzyme
SE421551B (sv) * 1980-03-26 1982-01-04 Sandvik Ab Borrverktyg for rotations- och/eller slagborrning
US4470973A (en) * 1982-07-19 1984-09-11 E. R. Squibb & Sons, Inc. Substituted peptide compounds
US4812442A (en) * 1984-05-29 1989-03-14 Merck & Co., Inc. Tripeptide renin inhibitors
FR2575753B1 (fr) * 1985-01-07 1987-02-20 Adir Nouveaux derives peptidiques a structure polycyclique azotee, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
AT383762B (de) * 1985-12-23 1987-08-25 Plansee Metallwerk Verfahren zur herstellung mehrkomponentiger, kongruent erschmelzender lotmaterialien
CA1286989C (en) * 1985-12-26 1991-07-30 A. Arthur Gottlieb Immunoamplifiers and related compositions
WO1988000939A1 (fr) * 1986-07-25 1988-02-11 Banyu Pharmaceutical Co., Ltd. Derives d'amino-alcools optiquement actifs et procede pour leur preparation
EP0264106B1 (en) * 1986-10-14 1994-03-16 Banyu Pharmaceutical Co., Ltd. 5-Substituted amino-4-hydroxy-pentanoic acid derivatives and their use
US4863905A (en) * 1987-02-04 1989-09-05 Warner-Lambert Company Renin inhibitors II
FR2610934B1 (fr) * 1987-02-13 1989-05-05 Adir Nouveaux derives peptidiques a structure polycyclique azotee, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
DE3717631A1 (de) * 1987-05-26 1988-12-15 Merck Patent Gmbh Aminosaeurederivate
DE3733296A1 (de) * 1987-10-02 1989-04-20 Merck Patent Gmbh Aminosaeurederivate
IL89900A0 (en) * 1988-04-12 1989-12-15 Merck & Co Inc Hiv protease inhibitors useful for the treatment of aids and pharmaceutical compositions containing them
DE4033062A1 (de) * 1990-10-18 1992-04-23 Merck Patent Gmbh Aminosaeurederivate
GB8927915D0 (en) * 1989-12-11 1990-02-14 Hoffmann La Roche Novel alcohols

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0346847A2 (en) 1988-06-13 1989-12-20 F. Hoffmann-La Roche Ag Amino acid derivatives

Also Published As

Publication number Publication date
HU211342A9 (en) 1995-11-28
NO905322L (no) 1991-06-12
FI973895A7 (fi) 1997-10-06
CA2030433C (en) 1997-10-21
CZ576590A3 (en) 1995-11-15
PL288201A1 (en) 1991-09-09
CN1034805C (zh) 1997-05-07
PT96145A (pt) 1991-09-30
SG120493G (en) 1994-01-21
GB2239016A (en) 1991-06-19
MX23619A (es) 1993-10-01
DE69019481D1 (de) 1995-06-22
IE67523B1 (en) 1996-04-03
BR9006264A (pt) 1991-09-24
SK280249B6 (sk) 1999-10-08
NO176566B (no) 1995-01-16
EP0432695A2 (en) 1991-06-19
LTIP862A (en) 1995-03-27
ID1018B (id) 1996-10-18
NL970013I2 (nl) 1997-09-01
FI973895A0 (fi) 1997-10-06
BG51452A3 (bg) 1993-05-14
CA2030433A1 (en) 1991-06-12
LV5738A4 (lv) 1996-08-20
CU22305A3 (es) 1995-01-31
FI905983A0 (fi) 1990-12-04
PT96145B (pt) 1998-04-30
DE69019481T2 (de) 1995-11-09
KR910011894A (ko) 1991-08-07
FI905983L (fi) 1991-06-12
FI973895L (fi) 1997-10-06
MX173630B (es) 1994-03-18
NO905322D0 (no) 1990-12-10
EP0432695A3 (en) 1991-12-18
MC2195A1 (fr) 1992-10-05
DK0432695T3 (da) 1995-09-11
CN1066329C (zh) 2001-05-30
HRP930341A2 (en) 1994-10-31
FI100883B (fi) 1998-03-13
EP0432695B1 (en) 1995-05-17
IS3651A7 (is) 1991-06-12
JPH03255076A (ja) 1991-11-13
CN1052482A (zh) 1991-06-26
IN172553B (OSRAM) 1993-09-25
PL165225B1 (pl) 1994-11-30
CZ280558B6 (cs) 1996-02-14
SK576590A3 (en) 1999-10-08
NO176566C (no) 1995-04-26
CN1138983A (zh) 1997-01-01
IL96550A (en) 1995-03-15
ES2072959T3 (es) 1995-08-01
LV5738B4 (lv) 1996-12-20
MA22014A1 (fr) 1991-07-01
NL970013I1 (nl) 1997-05-01
ZA909743B (en) 1991-08-28
HU207298B (en) 1993-03-29
RU2071470C1 (ru) 1997-01-10
SI9012315A (en) 1997-10-31
MTP1075B (en) 1991-07-31
EG19722A (en) 1996-01-31
HRP930341B1 (en) 1998-12-31
LU90014I2 (fr) 1997-01-31
GB8927913D0 (en) 1990-02-14
DE19675051I2 (de) 2001-04-12
IE904453A1 (en) 1991-06-19
OA09334A (fr) 1992-09-15
HK129093A (en) 1993-12-03
HU908076D0 (en) 1991-06-28
GR3017114T3 (en) 1995-11-30
ZW17490A1 (en) 1992-06-17
GB2239016B (en) 1993-08-04
MW8890A1 (en) 1991-03-13
KR970005912B1 (en) 1997-04-22
AU634319B2 (en) 1993-02-18
AU6787690A (en) 1991-06-13
DZ1467A1 (fr) 2004-09-13
RO107942B1 (ro) 1994-01-31
ATE122661T1 (de) 1995-06-15
SI9012315B (sl) 1998-06-30
JP2807093B2 (ja) 1998-09-30
US5196438A (en) 1993-03-23
IL96550A0 (en) 1991-09-16
IS1803B (is) 2002-02-26
HUT56073A (en) 1991-07-29
GB9026776D0 (en) 1991-01-30

Similar Documents

Publication Publication Date Title
LT3682B (en) Method for preparing amino acid derivatives and pharmaceuthical compositions thereof
US4294832A (en) Tetrahydroisoquinoline compounds and a pharmaceutical composition thereof
JP2515019B2 (ja) アミノ酸誘導体
AU606901B2 (en) Novel phosphinic acid derivatives
DE69416629T2 (de) 2-Piperazinon-Verbindungen und deren Verwendung
RU2232760C2 (ru) Ингибитор сериновых протеаз и фармацевтическая композиция на его основе
DE60221508T2 (de) Aminosäurederivate als hiv-protease-inhibitoren
KR20000016700A (ko) 뎁시 펩티드 및 이를 유효 성분으로 하는 의약
US4216209A (en) Tripeptide angiotensin converting enzyme inhibitors
US4587250A (en) Thiazaspirane derivatives, process for their preparation, and medicaments
KR870001239B1 (ko) 테트라하이드로-β-카르보린 유도체의 제조방법
FR2594831A1 (fr) Derives de proline, leur procede de preparation, composition pharmaceutique en comportant et procede d'inhibition de l'enzyme transformant l'angiotensine
JPH07126286A (ja) 新規なペプチド誘導体
BG60367B2 (bg) Аминокиселинни производни
JPH08259532A (ja) ペプチド様化合物又はその薬理的に許容される塩
JPH075633B2 (ja) アミノ酸誘導体その製造方法及び血圧降下剤
RU2109731C1 (ru) Производные аминокислоты и их фармацевтически приемлемые соли, которые являются основными, способы получения производных аминокислоты и фармацевтическая композиция, обладающая антивирусной активностью
SA90110168B1 (ar) مشتقات الاحماض الامينية.
JPH07157472A (ja) ２−ピペラジノン−１−酢酸誘導体およびその用途

Legal Events

Date Code Title Description
SPCF Filing an spc

Free format text: PRODUCT NAME: (S)-N-((ALFAS)-ALFA-((1R)-2-((3S,4AS,8AS)-3-(TRET-BUTILKARBAMOIL)OKTAHIDRO-2(1H)-IZOCHINOLIL)-1-HIDROKSIETIL)-2-CHINALDAMIDO SUKCINAMIDAS, MEZILATAS (SAQUINAVIR); REGISTRATION NO/DATE: EU/1/96/026/001 19961004

Spc suppl protection certif: PA2004003

Filing date: 20040730

Expiry date: 20130816

SPCR Rejection of an spc

Free format text: PRODUCT NAME: (S)-N-((ALFAS)-ALFA-((1R)-2-((3S,4AS,8AS)-3-(TRET-BUTILKARBAMOIL)OKTAHIDRO-2(1H)-IZOCHINOLIL)-1-HIDROKSIETIL)-2-CHINALDAMIDO SUKCINAMIDAS, MEZILATAS (SAQUINAVIR); REGISTRATION NO/DATE: EU/1/96/026/001 19961004

Spc suppl protection certif: PA2004003

Filing date: 20040730

Expiry date: 20130816

Effective date: 20050927

MK9A Expiry of a patent

Effective date: 20130816